UnitedHealth Weighs on Dow: Stock Market Update

Market Volatility and Key Developments

Stocks opened higher on Tuesday, with the S&P 500 and Nasdaq Composite heading toward record highs. However, by lunchtime, the main indexes experienced a decline as investors analyzed recent corporate earnings reports and anticipated the conclusion of the July Federal Reserve meeting.

One of the most significant stock movements came from Novo Nordisk (NVO), which saw its shares drop by 21.8% after the company revised its 2025 outlook downward. The Danish drugmaker now expects revenue growth of 11% at the midpoint and operating profit growth of 13%, compared to previous projections of 17% and 20% growth.

The reduced guidance was attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration of Wegovy in certain regions. Shortages of the weight-loss drugs allowed compounding pharmacies to produce knockoff versions, increasing competition and reducing demand. In a separate statement, Novo Nordisk announced that Maziar Mike Doustdar will take over as CEO from Lars Fruergaard Jorgensen, effective August 7.

Procter & Gamble Faces Challenges

On the earnings calendar, Procter & Gamble (PG) reported higher-than-expected fiscal fourth-quarter earnings of $1.48 per share, with revenue reaching $20.9 billion. For fiscal 2026, the company anticipates net sales to grow by 3% and earnings per share to increase by 2% at the midpoint of their respective ranges. However, this outlook includes a $1 billion headwind from President Donald Trump’s tariff policies.

To mitigate the impact of these tariffs, PG plans to raise prices on roughly a quarter of its products. Additionally, the company announced that Shailesh Jejurikar, its current chief operating officer, will succeed Jon Moeller as CEO, effective January 1, 2026.

UnitedHealth Group Struggles with Guidance

UnitedHealth Group (UNH) was one of the worst-performing Dow Jones stocks, dropping 7.5% after providing weak full-year guidance. The company cited rising medical costs as a key factor in its disappointing outlook. During the earnings call, UnitedHealthcare CEO Tim Noel admitted that the company underestimated the accelerating medical trend when preparing its 2025 Medicare Advantage offerings.

In its second-quarter results, UnitedHealth reported earnings of $4.08 per share, which fell short of expectations, despite slightly higher revenue of $111.6 billion.

Mergers and Market Trends

In non-earnings news, Union Pacific (UNP) announced it would acquire fellow railroad Norfolk Southern (NSC) for $320 per NSC share. The cash-and-stock deal gives Norfolk an enterprise value of approximately $85 billion. If approved by regulators, the merger would create the country's first transcontinental railroad. However, both UNP and NSC saw declines in their stock prices, with UNP dropping 2.4% and NSC falling 3.0%.

Index Performance and Economic Indicators

By the end of the trading day, the Dow Jones Industrial Average fell 0.5% to 44,632, the S&P 500 shed 0.3% to 6,370, and the Nasdaq Composite gave back 0.4% to 21,098.

Ahead of the Fed meeting, data from the Bureau of Labor Statistics showed job openings declined to 7.4 million in June, down from 7.7 million in May. Elizabeth Renter, senior economist at NerdWallet, noted that the job market remained sluggish due to uncertainty among employers. Many businesses are delaying hiring and firing decisions until there is more clarity on the impact of tariffs.

The Federal Reserve is expected to maintain a wait-and-see approach in its upcoming policy statement, with Fed Chair Jerome Powell likely to emphasize a data-dependent strategy. The central bank will closely monitor how tariffs affect inflation before making further decisions.

Looking Ahead

As the market continues to react to earnings, mergers, and economic indicators, investors remain cautious about the potential impact of ongoing uncertainties. With the Fed meeting approaching, the focus will be on whether the central bank will signal any changes in monetary policy.